Personalis Announces Updates to NeXT Platform™ Incorporating Additional Key Profiling Capabilities for Advancing Oncology Biomarkers
3.11.2021 02:01:00 EET | Business Wire | Press release
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the latest expansion of the Personalis NeXT Platform® adding several new features that are key to the understanding of the interactions between the tumor and the immune system and how they may influence a cancer patient’s response to therapy.
The new and improved features include:
- InfiltrateID™, a sophisticated analytics module that leverages the augmented gene expression data from the NeXT Transcriptome™ to detect the presence of eight immune cell populations within a tumor sample
- RepertoireID™ now incorporates the characterization of the B-cell receptor repertoire, including the computing of isotype makeup, as a complement to the previously released T-cell receptor repertoire feature
- SHERPA™, further enhancing the performance of Personalis’ leading pan-allelic neoantigen prediction algorithm recently published in the Immunopeptidomics Special Issue of the journal Molecular & Cellular Proteomics
Personalis CMO and SVP of R&D, Richard Chen, MD, said, “With the ability to identify immune cell populations in the tumor, characterize the B-cell and T-cell receptor repertoires, and better predict neoantigens, we are further expanding the NeXT Platform for additional emerging oncology biomarkers. As we recently demonstrated with our NEOPS biomarker publication, combining both tumor and immune features into a composite biomarker can lead to better stratification of patient response to cancer therapy. These new NeXT Platform features open up opportunities to further enhance composite biomarkers like NEOPS.”
These advanced machine learning and algorithmic tools paired with the unique assay design of the NeXT Platform, further Personalis’ goal of providing the most comprehensive genomic tumor profiling platform available. The NeXT Platform consolidates multiple biomarker assays into one, enabling a seamless path from translational research to companion diagnostics development.
About Personalis, Inc.
Personalis, Inc. is a leader in advanced cancer genomics for enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. In population sequencing, Personalis operates one of the largest sequencing operations globally and is currently the sole sequencing provider to Veterans Affairs' Million Veteran Program. To enable cancer and population sequencing, Personalis' Clinical Laboratory has been built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit www.personalis.com and follow Personalis on LinkedIn and Twitter.
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of InfiltrateID, RepertoireID, SHERPA, NEOPS, or the Personalis NeXT Platform, Personalis’ business opportunities, leadership, plans, vision or growth, or other future events. Such forward-looking statements involve risks and uncertainties, including those related to the COVID-19 pandemic, that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211102006387/en/
Contact information
Investor Relations Contact for Personalis:
Caroline Corner
investors@personalis.com
www.westwicke.com
415-202-5678
Media Contact for Personalis:
Jennifer Havlek
pr@personalis.com
www.personalis.com
650-752-1300
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Update Settlement Infrastructure for New Games, Build Multi-Rail Trust Layer, and Close the Accessibility Gap in AI Economy: Ant International’s Peng Yang at SFF 202619.11.2026 14:05:00 EET | Press release
At the Singapore FinTech Festival, Ant International CEO Peng Yang (YP) joined Javier Pérez-Tasso of Swift and Surendra Rosha of HSBC on the panel “From Digital to Intelligent: Who Will Build the Next Financial System?”, moderated by Arjun Vir Singh of Arthur D. Little. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119101038/en/ Ant International at the Singapore Fintech Festival 2026 YP highlighted three critical angles to tackle the future financial system: How should settlement infrastructure evolve in the AI + blockchain era to establish new game rules? How to build cross-rail, cross-modal trust for the agentic economy? How to mainstream inclusion into AI design to close the accessibility gap for SMEs? The Missing Debate: Rewiring settlement infrastructure The four-party payment model — issuer, acquirer, network, regulator — has served as a mature bedrock for traditional economy. However, would we still need the acqu
NIQ Appoints Danny Lange and Chris Tung to Board of Directors19.11.2026 13:45:00 EET | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that Danny Lange and Chris Tung have been appointed to its Board of Directors, effective Nov. 18, 2026. Lange brings more than three decades of technology leadership, including senior roles building and scaling artificial intelligence and machine learning capabilities at Google, Unity, Uber, Amazon and Microsoft. Tung brings extensive operating, consumer and digital commerce experience across Greater China and Asia Pacific through leadership roles at Shangri-La Asia, Alibaba, PepsiCo, L’Oréal and other global businesses. Together, their experience strengthens the Board’s perspective as NIQ advances its AI strategy and expands its impact across global markets. “Danny and Chris bring expertise that directly aligns with where NIQ is going,” said Jim Peck, Executive Chairman and Chief Executive Officer of NIQ. “Danny has spent his career building AI and machine learning capabilities at scale. Chris brings deep
Compass Pathways to Participate in 9th Annual Evercore Healthcare Conference on December 119.11.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the 9th Annual Evercore Healthcare Conference on December 1, 2026 and will participate in a fireside chat at 3:25pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/FkwyWrnNgoveMhBfJS2NCC/We7ydUWZPZM5Wf4zVRNZnZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treatment under evaluation f
SRM and Ridgemont Equity Partners Announce Strategic Partnership to Accelerate Next Phase of Growth19.11.2026 13:00:00 EET | Press release
Strategic Resource Management (SRM), a trusted, tech-enabled advisory firm serving financial institutions globally, today announced a strategic investment from Ridgemont Equity Partners, a middle market private equity investor. Building on over three decades of experience serving financial institutions and fintechs, this recapitalization aims to further strengthen SRM’s capabilities, talent, systems, and resources. Brad Downs, Chief Executive Officer and Chairman, and SRM’s existing leadership team will continue to lead the company into its next phase of growth. “SRM is a market-leading advisory firm with a strong reputation and proven track record, and is led by a very experienced executive team with a passion for delivering measurable results and meaningful business impact. SRM is an excellent fit with our experience in Business and Technology Services, and we see multiple ways to add value alongside the team as SRM’s first institutional investor. We’re excited to partner with Brad D
Pretium Expands Real Estate Debt Platform19.11.2026 13:00:00 EET | Press release
Pretium, a specialized investment firm with approximately $70 billion in assets under management, today announced it is expanding its residential real estate debt platform, further enabling the flow of capital to real estate investors, developers and homebuilders. Since launching its residential debt platform in December 2024, Pretium has lent approximately $8 billion for the purpose of new housing construction and the renovation of existing homes. Building on its existing model, Pretium is adding the team from Hilltop Capital Partners (“Hilltop”), a specialized U.K.-based institutional capital advisor, investment manager and principal lender, to its vertically integrated residential real estate platform. Led by Paul Oberschneider and Tiger Craft, Hilltop has grown into a leading platform for residential development finance across the U.K since its founding in 2019. “The U.K. faces a housing shortage of approximately four to five million homes, and the Hilltop team has built an impress
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
